You are here

Pivotal Phase 3 Studies Planned for Treatment of <i>Clostridium Difficile</i>-Associated Diarrhea

The studies are designed to compare the end-of-therapy response rates with CB-315 and oral vancomycin and to evaluate the safety of CB-315 in patients with CDAD. In addition, investigators will look at sustained clinical response after treatment.

CDAD is a disease caused by an overgrowth of, and subsequent toxin production by, C. difficile, a resident anaerobic spore-forming Gram-positive bacterium of the lower gastrointestinal (GI) tract. The overgrowth of C. difficile in the GI tract is caused by the use of antibiotics for the treatment of common community and hospital-acquired infections. Although antibiotics treat the underlying infection, many of these drugs disrupt the natural gut flora and allow C. difficile to proliferate. C. difficile produces toxins that can lead to severe diarrhea, sepsis, and even death.

For more information, visit

Recent Headlines

Possible First Treatment Option for Rare Autoimmune Disease of the CNS
New Hematologic Biomarker Test Provides New Approach to Sepsis Triage and Diagnosis
Antibiotics, Statins, and Glucocorticoids All Show Promise
Current, Sole Therapy Not Always Successful/Suitable
Over 1.5 Million Americans Likely to have Wet AMD by 2020 
Potential For Use Against E. Coli, TB, Resistant Bacteria
More Than 32% of Patients Responded in Trial
Evenity Increases New Bone Formation, Lowers Vertebral Fracture Potential